卵巢交界性肿瘤的新超声标志:乳头状突起和实性成分的微囊型模式
回顾性分析62例(67个卵巢)经手术病理证实为卵巢交界性肿瘤(BOT)患者的术前经阴道超声图像,评估乳头状突起、实性成分和/或分隔内1-3 mm薄壁液性微囊簇这一新征象。67个BOT中60个(89.6%)见微囊型模式,而20例上皮性卵巢癌和20例良性囊腺瘤均未见此征象。
要点
- BOT的乳头状突起、实性成分和/或分隔内可见1-3 mm薄壁液性微囊簇,67个BOT中60个(89.6%)出现。
- 浆液性BOT 46/47(97.9%)、黏液性BOT 11/15(73.3%)、浆液黏液性BOT 3/5(60.0%)可见微囊型模式。
- 20例上皮性卵巢癌和20例良性囊腺瘤在超声和组织学上均未见微囊型特征。
核心结论
- 作者报告了一种新的BOT超声标志——乳头状突起、实性成分和/或分隔的「微囊型模式」,该征象似乎为BOT所特有,有助于将BOT与卵巢癌和良性卵巢病变区分开。
研究设计与样本
- 回顾性研究,纳入62例(67个卵巢)术前经阴道超声检查、术后病理证实为BOT的患者,平均手术年龄39.8岁,平均BOT大小60.7 mm;另随机选取20例上皮性卵巢癌和20例良性囊腺瘤作对照,由同一病理医师复核;并检索PubMed 2010至2018年英文文献。
关键影像表现/征象
- 经阴道超声上,BOT的乳头状突起、实性成分和/或分隔内可见薄壁、液性、1-3 mm囊性结构组成的簇状微囊型模式。
- 67个BOT中60个(89.6%)见微囊型模式,包括浆液性46/47(97.9%)、黏液性11/15(73.3%)、浆液黏液性3/5(60.0%)。
- 组织学上67个样本中60个(89.6%)见与超声所见类似的1-3 mm液性囊肿,7例超声与组织学观察不一致。
- 20例囊腺瘤多为单房和/或多房、大部分无血流信号,20例上皮性卵巢癌在超声和组织学上均未见微囊型特征。
诊断标准与关键数值
- 微囊型模式定义为与实性成分、乳头状突起和/或分隔相关的薄壁、液性、1-3 mm囊性结构簇。
- 67个BOT中60个(89.6%)经阴道超声见微囊型模式,组织学上60/67(89.6%)见类似1-3 mm液性囊肿。
- 20例上皮性卵巢癌和20例良性囊腺瘤均未见微囊型特征。
临床应用与阅片要点
- 作者认为,应用这一新标志应有助于正确识别BOT,将其与卵巢癌和良性卵巢病变区分开,并有助于确保适当的临床和手术处理。
局限性
- 原文为回顾性研究,纳入62例(67个卵巢)经手术病理证实为BOT的患者。
- 7例超声与组织学观察微囊型模式不一致。
- 作者检索PubMed 2010至2018年英文文献23篇(含163幅BOT超声图像),发现所有图像均含该征象但未见对其的描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To describe and evaluate the utility of a new sonographic microcystic pattern, which is typical of borderline ovarian tumor (BOT) papillary projections, solid component(s) and/or septa, as a new ultrasound marker that is capable of distinguishing BOT from other adnexal masses, and to present/obtain histologic confirmation.
METHODS: In this retrospective study, we identified women with a histologic diagnosis of BOT following surgical resection who had undergone preoperative transvaginal ultrasound (TVS) examination. All images were reviewed for presence or absence of thin-walled, fluid-filled cluster(s) of 1-3-mm cystic formations, associated with solid component(s), papillary projections and/or septa. From the same cases, histopathologic slides of each BOT were examined for presence of any of these microcystic features which had been identified on TVS. To confirm that the microcystic TVS pattern is unique to BOTs, we also selected randomly from our ultrasound and surgical database 20 cases of epithelial ovarian cancer and 20 cases of benign cystadenoma, for review by the same pathologists. To confirm the novelty of our findings, we searched PubMed for literature published in the English language between 2010 and 2018 to determine whether the association between microcystic tissue pattern and BOT has been described previously.
RESULTS: Included in the final analysis were 62 patients (67 ovaries) with preoperative TVS and surgically confirmed BOT on pathologic examination. The mean patient age at surgery was 39.8 years. The mean BOT size at TVS was 60.7 mm. Of the 67 BOTs, 47 (70.1%) were serous, 15 (22.4%) were mucinous and five (7.5%) were seromucinous. We observed on TVS a microcystic pattern in the papillary projections, solid component(s) and/or septa in 60 (89.6%) of the 67 BOTs, including 46 (97.9%) of the 47 serous BOTs, 11 (73.3%) of the 15 mucinous BOTs and three (60.0%) of the five seromucinous BOTs. On microscopic evaluation, 60 (89.6%) of the 67 samples had characteristic 1-3-mm fluid-filled cysts similar to those seen on TVS. In seven cases there was a discrepancy between sonographic and histologic observation of a microcystic pattern. The 20 cystadenomas were mostly unilocular and/or multilocular and largely avascular. None of them or the 20 epithelial ovarian malignancies displayed microcystic characteristics, either on TVS or at histology. On review of 23 published articles in the English medical literature, containing 163 sonographic images of BOT, we found that, while all images contained it, there was no description of the microcystic tissue pattern.
CONCLUSION: We report herein a novel sonographic marker of BOT, a 'microcystic pattern' of BOT papillary projections, solid component(s) and/or septa. This was seen in the majority of both serous and mucinous BOT cases. Importantly, based on comparison of sonographic images and histopathology of benign entities and malignancies, the microcystic appearance seems to be unique to BOTs. No similar description has been published previously. Utilization of this new marker should help to identify BOT correctly, discriminating it from ovarian cancer and benign ovarian pathology, and should ensure appropriate clinical and surgical management. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Timor-Tritsch IE, Foley CE, Brandon C, et al. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components. Ultrasound Obstet Gynecol. 2019. PMID: 30950132. doi:10.1002/uog.20283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。